Longboard Pharma (LBPH) Market Cap to Earnings

Corporate emblem and logo of Longboard Pharma (LBPH)

The market trend for Longboard Pharmaceuticals (LBPH) reflects the dynamics of a company developing advanced, patent-protected treatments for epilepsy and severe brain pathologies. The current indicator stands at -27.00. Despite reliance on a single primary project, significant capital ensures financial stability. The brand's high medical authority is based on effective trials and providing aid to patients with rare diagnoses.

Longboard Pharmaceuticals - LBPH P/E Multiple (period 07/04/2022 - 12/07/2024)

Analytical breakdowns for Longboard Pharmaceuticals

- stock quotes and analyst forecast:
Price Chart longboardpharma.com|LBPH - Price Target Chart
- market capitalization details:
Market Value Longboard Pharmaceuticals, Inc.|LBPH - Total Company Value
- book value of equity indicators:
Equity per Share Longboard Pharmaceuticals|LBPH - Book Capitalization|Market Value to Equity Ratio longboardpharma.com|LBPH - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Longboard Pharmaceuticals|LBPH - Long-Term Debt to Equity|Current Liabilities to Capital Longboard|LBPH - Company Aggregate Debts|Debts to Book Capitalization Longboard Pharmaceuticals, Inc.|LBPH - Company Long-Term Debt|Company Short-Term Loans and Borrowings Longboard Pharmaceuticals|Immediate Liquidity Ratio longboardpharma.com
- financial results and valuation multiples details:
LBPH - Net Income|Expected Net Income Longboard Pharmaceuticals|LBPH - Price to Earnings Ratio|Price to Expected Earnings Ratio Longboard Pharmaceuticals Inc|LBPH - PEG Multiple|Business Value to Operating Income Before Depreciation Longboard Pharmaceuticals, Inc.|LBPH - Operating profit EBITDA|Net earnings per share (EPS TTM) Longboard Pharmaceuticals|LBPH - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months longboardpharma.com|LBPH - Earnings per share growth in current year|Expected earnings per share growth for next year Longboard Pharmaceuticals
- company sales and revenue statistics:
LBPH - Revenue and Sales Volume|Projected Sales Volume longboardpharma.com|LBPH - P/S Multiple|Forward Price-to-Revenue Multiple Longboard Pharmaceuticals, Inc.
Summary company analysis:LBPH, longboardpharma.com
Brand item of Longboard Pharmaceuticals, Inc.

The P/E ratio measures the market value of a single unit of net profit, determining the investment payback period. This metric compares current market capitalization with the actual profitability of the business. By monitoring P/E fluctuations, an investor can see the impact of the acquisition of Longboard Pharmaceuticals (LBPH) by a European behemoth on asset valuation. The integration of the pipeline into the buyer's structure renders classic earnings analysis secondary. The indicator now serves as a marker for the completion of the M&A transaction.

Analysis of competing companies

Price to Earnings Ratio BIIB|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|RGC - Market Cap to Earnings|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACAD: Price to Earnings Multiple|Xenon Pharmaceuticals - P/E Multiple|Market Cap to Net Income Ratio vikingtherapeutics.com (VKTX)|SUPN: P/E Multiple|CPRX (Catalyst Pharma) - Price to Earnings Ratio|Price to Earnings Ratio Denali Therapeutics Inc|Market Cap to Earnings Harmony Corp HRMY|P/E Multiple BHVN|P/E Multiple amylyx.com (AMLX)|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|Company Value to Net Income PRAX|Anavex Corp - P/E Multiple|CBLL (CeriBell EEG) - Price to Earnings Multiple|PRTA (prothena.com) - Price to Earnings Ratio|Alector - Company Value to Net Income|Price to Earnings Ratio Annexon|Omeros Corp. - Market Cap to Net Income|P/E Multiple NGNE|ACIU (AC Immune Inc) - Company Value to Net Income|P/E Multiple VYGR (Voyager Therapeutics)|P/E Multiple neumoratx.com NMRA|SCLX - Price to Earnings Ratio|Company Value to Net Income TVGN (Tevogen Bio Holdings Inc.)|alphacognition.com (ACOG) - Price to Earnings Ratio|Price to Earnings Ratio Cognition Therapeutics Inc.|IKT (Inhibikase Therapeutics) - P/E Multiple|P/E Multiple cassavasciences.com|P/E Multiple ASRT|Price to Earnings Ratio coyatherapeutics.com COYA|P/E Multiple VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Market Cap to Earnings|ABOS: Price to Earnings Ratio|CRVO - P/E Multiple|ATHE (alteritytherapeutics.com) - Price to Earnings Ratio|CLNN: Market Price to Net Income Ratio|PEPG (PepGen Inc) - P/E Multiple|Jupiter Neurosciences, Inc. (JUNS) - Business Payback Period|P/E Multiple RLMD|Price to Earnings Ratio annovisbio.com ANVS|P/E Multiple GRCE (Grace Therapeutics)|P/E Multiple Firefly Neuroscience, Inc. AIFF|KLTO - Price to Earnings Ratio|NRSN: Price to Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA - Business Payback Period|Price to Earnings Ratio NeurAxis|Price to Earnings Ratio HSDT|P/E Multiple PASG|Price to Earnings Ratio NEUP (bionomics.com.au)|Price to Earnings Ratio Minerva Neurosciences NERV|ATHA (athira.com) - Market Cap to Net Income|Addex Therapeutics Ltd - P/E Multiple|Company Value to Net Income ALZN (Alzamend Neuro, Inc.)|cyclerion.com (CYCN) - Price to Earnings Ratio|Price to Earnings Multiple PTIX|KTTA (Pasithea Therapeutics Corp) - P/E Multiple|Market Cap to Earnings Cortigent Medical CRGT|Price to Earnings Ratio ATXI (Avenue Therapeutics, Inc.)|P/E Multiple Brainstorm Cell Therapeutics Inc. (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|Company Value to Net Income CHRO|ELYM - Price to Earnings Ratio|Market Cap to Earnings Intra-Cellular Therapies|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|NKGN (NKGen Biotech Inc) - Price to Earnings Ratio|Price to Earnings Ratio NeuroBo|Market Cap to Earnings Sage Therapeutics Inc SAGE|Price to Earnings Ratio Synaptogenix, Inc. (SNPX)|trevena.com - Price to Earnings Multiple|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|Market Cap to Net Income Ratio anewmeds.com|Cerevel - P/E Multiple